 SAN DIEGO and TORONTO, June 11, 2021 GLOBE NEWSWIRE -- Aptose Biosciences Inc. Aptose or the Company NASDAQ: APTO, TSX: APS, a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, is releasing highlights from a corporate update event being held today, Friday, June 11, 2021, at 8:00 a.m. ET, in concurrence with participation at the EHA2021 Virtual Congress EHA. The event is focused on the current clinical status of luxeptinib, Aptoses oral, first-in-class FLT3 and BTK kinase inhibitor currently in two Phase 1 ab trials, one trial in patients with relapsed or refractory acute myeloid leukemia AML, and the other trial in patients with relapsed or refractory B cell malignancies. The live and archived webcast of the presentation is available on Aptoses website here. 